References
- Centers for Disease Control and Prevention (CDC)Prevalence of disabilities and associated health conditions among adults – United States, 1999MMWR Morb Mortal Wkly Rep200150712012511393491
- SimonJMcAuliffeMShamimFVuongNTahaeiADiscogenic low back painPhys Med Rehabil Clin N Am201425230531724787335
- GBD 2015 Disease and Injury Incidence and Prevalence CollaboratorsGlobal, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015Lancet2016388100531545160227733282
- FrymoyerJWThe Adult Spine: Principles and PracticePhiladelphia, PALippincott-Raven1997
- CroftPRigbyASBoswellRSchollumJSilmanAThe prevalence of chronic widespread pain in the general populationJ Rheumatol19932047107138496870
- RubinDIEpidemiology and risk factors for spine painNeurol Clin200725235337117445733
- JarvikJGDeyoRADiagnostic evaluation of low back pain with emphasis on imagingAnn Intern Med2002137758659712353946
- LaneNESchnitzerTJBirbaraCAMokhtaraniMSheltonDLSmithMDBrownMTTanezumab for the treatment of pain from osteoarthritis of the kneeN Engl J Med2010363161521153120942668
- AbdicheYNMalashockDSPonsJProbing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensorsProtein Sci20081781326133518505735
- HallidayDAZettlerCRushRAScicchitanoRMcNeilJDElevated nerve growth factor levels in the synovial fluid of patients with inflammatory joint diseaseNeurochem Res19982369199229572681
- ZhaoLRenTHWangDDClinical pharmacology considerations in biologics developmentActa Pharmacol Sin201233111339134723001474
- JonssonENXieRMarshallSFArendsRHPopulation pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis painBr J Clin Pharmacol201681468869926613544
- PaulWEImmunology: structure and functionPaul WE Fundamental immunology4th edPhiladelphia, PALippencott-Raven1999
- AkileshSHuberTBWuHPodocytes use FcRn to clear IgG from the glomerular basement membraneProc Natl Acad Sci U S A2008105396797218198272
- WangDDZhangSZhaoHMenAYParivarKFixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trialsJ Clin Pharmacol20094991012102419620385
- United States Food and Drug AdministrationTanezumab Arthritis Advisory Committee Briefing DocumentUSFDA2016 Available from: http://www.fda.gov/downloads/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm295205.pdfAccessed February 4, 2018
- HochbergMCTiveLAAbramsonSBWhen is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the Tanezumab Clinical Development ProgramArthritis Rheumatol201668238239126554876
- KatzNBorensteinDGBirbaraCBramsonCNemethMASmithMDBrownMTEfficacy and safety of tanezumab in the treatment of chronic low back painPain2011152102248225821696889
- KivitzAJGimbelJSBramsonCEfficacy and safety of tanezumab versus naproxen in the treatment of chronic low back painPain201315471009102123628600
- GimbelJSKivitzAJBramsonCLong-term safety and effectiveness of tanezumab as treatment for chronic low back painPain201415591793180124937440
- LeiteVFBuehlerAMEl AbdOAnti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysisPain Physician2014171E45E6024452657
- KnezevicNNMandaliaSRaaschJKnezevicICandidoKDTreatment of chronic low back pain – new approaches on the horizonJ Pain Res2017101111112328546769
- BannwarthBKostineMTargeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?Drugs201474661962624691709
- PfizerA phase 3 study of tanezumab for chronic low back pain (TANGO) Available from: https://Clinicaltrials.gov/ct2/show/NCT02528253. NLM identifier: NCT02528253Accessed February 4, 2018
- PfizerLong term safety and efficacy study of tanezumab in Japanese adult subjects with chronic low back pain (TANGO) Available from: https://clinicaltrials.gov/ct2/show/record/NCT02725411?term=tanezumab&cond=Chronic+Low-back+Pain&rank=1. NLM identifier: NCT02725411Accessed February 4, 2018